Log In
Print
BCIQ
Print
Print this Print this
 

Gardasil, Silgard

  Manage Alerts
Collapse Summary General Information
Company Merck & Co. Inc.
DescriptionHPV types 6, 11, 16 and 18 recombinant vaccine
Molecular Target Not applicable
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: DNA vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationHuman papillomavirus (HPV)
Indication DetailsDetermine the prevalence of human papillomavirus (HPV) infection among females in the U.S.; Prevent anal intraepithelial neoplasia (AIN) and anal cancer associated with HPV types 6, 11, 16 and 18 in men and women ages 9-26; Prevent anal intraepithelial neoplasia (AIN) associated with HPV types 6, 11, 16 and 18 in men ages 16-26; Prevent cervical cancer, vulvar and vaginal cancers, precancerous lesions and genital warts caused by HPV types 6, 11, 16 and 18 in women ages 9-45; Prevent external genital lesions caused by HPV in males; Prevent genital warts caused by human papillomavirus (HPV); Prevent HPV infection; Prevent HPV-related anal dysplasia and anal cancer; Prevent human papillomavirus (HPV) types 6, 11, 16 and 18-related persistent infection, cervical and genital disease in women ages 24-45; Prevent premalignant genital lesions, cervical cancer causally related to certain oncogenic HPV types and genital warts causally related to specific HPV types in girls and boys ages >=9 years; To prevent cervical cancer and its precancerous lesions, vulvar and vaginal precancerous lesions and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older
Regulatory Designation

Partner

Sanofi


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today